Development of an osteogenic bone-marrow preparation.

Connolly, John F.; Guse, Roy; Lippiello, Louis; Dehne, Robert

doi:10.2106/00004623-198971050-00007

Cited by 219 publications

(105 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has been recapitulated by different articles, particularly in the field concerning bone marrow-derived stem cells [3][4][5]. As one of every 100,000 nucleated cells derived from bone marrow is a stem cell, a procedure of isolation is required to decrease the volume of material injected [6]. Recently, a highly purified population of stromal stem cells derived from human bone marrow was described [7].…”

Section: Introductionmentioning

confidence: 99%

Fetal bone cells for tissue engineering

Montjovent

Burri

Mark

et al. 2004

Bone

View full text Add to dashboard Cite

We envision the use of human fetal bone cells for engineered regeneration of adult skeletal tissue. A description of their cellular function is then necessary. To our knowledge, there is no description of human primary fetal bone cells treated with differentiation factors. The characterization of fetal bone cells is particularly important as the pattern of secreted proteins from osteoblasts has been shown to change during aging. In the first part of this work, human primary fetal bone cells were compared to adult bone cells and mesenchymal stem cells for their ability to proliferate and to differentiate into osteoblasts in vitro. Cell proliferation, gene expression of bone markers, alkaline phosphatase (ALP) activity, and mineralization were analyzed during a time-course study. In the second part of this paper, bone fetal cells behavior exposed to osteogenic factors is further detailed. The doubling time of fetal bone cells was comparable to mesenchymal stem cells but significantly shorter than for adult bone cells. Gene expression of cbfa-1, ALP, a1 chain of type I collagen, and osteocalcin were upregulated in fetal bone cells after 12 days of treatment, with higher inductions than for adult and mesenchymal stem cells. The increase of ALP enzymatic activity was stronger for fetal than for adult bone cells reaching a maximum at day 10, but lower than for mesenchymal stem cells. Importantly, the mineralization process of bone fetal cells started earlier than adult bone and mesenchymal stem cells. Proliferation of fetal and adult bone cells was increased by dexamethasone, whereas 1a,25-dihydroxyvitamin D 3 did not show any proliferative effect. Mineralization studies clearly demonstrated the presence of calcium deposits in the extracellular matrix of fetal bone cells. Nodule formation and calcification were strongly increased by the differentiation treatment, especially by dexamethasone. This study shows for the first time that human primary fetal bone cells could be of great interest for bone research, due to their fast growth rate and their ability to differentiate into mature osteoblasts. They represent an interesting and promising potential for therapeutic use in bone tissue engineering.

show abstract

Section: Introductionmentioning

confidence: 99%

Fetal bone cells for tissue engineering

Montjovent

Burri

Mark

et al. 2004

Bone

View full text Add to dashboard Cite

show abstract

“…Bone marrow aspirate (BMA) is a source of pluripotent cells and its use in combination with HA and β-TCP bone substitute materials has been shown to have a significant effect on increasing bone regeneration within the scaffold (26 -28). Although the number of stromal cells present within BMA are relatively low compared to treatments where these cells have been expanded in vitro, the direct use of BMA in augmenting bone healing avoids regulatory issues and is significantly less expensive (36).…”

Section: Introductionmentioning

confidence: 99%

The effect of an alginate carrier on bone formation in a hydroxyapatite scaffold

et al. 2015

View full text Add to dashboard Cite

This study investigated the osteoconductive properties of a porous hydroxyapatite (HA) scaffold manufactured using a novel technique similar to the bread-making process, alone and in combination with an alginate polysaccharide fibre gel (HA/APFG putty) and autologous bone marrow aspirate (BMA). The hypothesis was that the HA/APFG putty would be as osteoconductive as granular HA and that the presence of BMA would further enhance bone formation in an ovine femoral condyle critical defect model. Thirty-six defects were created and either (1) porous HA granules, (2) HA/APFG putty or (3) HA/APFG putty + BMA were implanted. Following retrieval at 6 and 12 weeks, image analysis techniques were used to quantify bone apposition rates, new bone area, bone-HA scaffold contact and implant resorption.At 6 weeks post-surgery, significantly lower bone apposition rates were observed in the HA/APFG putty group when compared to the HA (p = 0.014) and HA/APFG putty + BMA (p = 0.014) groups. At 12 weeks, significantly increased amounts of new bone formation was measured within the HA scaffold (33.56 ± 3.53%) when compared to both the HA/APFG putty (16.69 ± 2.7%; p = 0.043) and defects containing HA/APFG putty + BMA (19.31 ± 3.8%; p = 0.043).The use of an alginate polysaccharide fibre gel as a carrier for injectable CaP bone substitute materials delayed bone formation in this model compared to HA granules alone which enhanced bone formation especially within the interconnected smaller pores. Our results also showed that the addition of autologous bone marrow aspirate did not further enhance its osteoconductive properties. Further work is Does an Alginate Gel Carrier Effect Bone Formation? 2 required to optimize the degradation rate of this alginate polysaccharide fibre gel binging agent before use as a directly injectable material used for bone defect repair.

show abstract

“…McGaw and Habin were among the first to demonstrate the osteogenic activity of bone marrow 3 . The concept of percutaneous bone marrow was introduced by Herzog in 1951 4 . Connolly and Shindell were, to our knowledge, the first to report on the percutaneous injection of bone marrow to bring about healing of an infected ununited tibia 4 .…”

Section: Introductionmentioning

confidence: 99%

“…The concept of percutaneous bone marrow was introduced by Herzog in 1951 4 . Connolly and Shindell were, to our knowledge, the first to report on the percutaneous injection of bone marrow to bring about healing of an infected ununited tibia 4 . Osteogenicity of bone marrow has been traced and attributed to the stromal and endosteal cells of the marrow.…”

Section: Introductionmentioning

confidence: 99%

MULTIPLE CUTANEOUS METASTASIS FROM CARCINOMA OF THE UTERINE CERVIX Â€“ a CASE REPORT

Tayade¹,

Kumar²,

Shivkumar³

2012

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

<p>Metastasis to the skin occurs rarely in gynaecologic cancers and especially so in cervical carcinoma. Although carcinoma of the cervix is the second most common malignancy in Indian woman, cutaneous involvement originating from cervical cancer is particularly unusual, even in the terminal stage of the disease. This cutaneous metastasis can be confused with dermatitis and the diagnosis can be missed unless care is taken to perform an FNAC. Their presence however signals a poor prognosis. Palliative chemotherapy and radiotherapy have a useful role in controlling symptoms. We are presenting aÂ rare case of skin and subcutaneous tissue metastasis from cervical cancer at multiple sites.</p>

show abstract

Development of an osteogenic bone-marrow preparation.

Cited by 219 publications

References 18 publications

Fetal bone cells for tissue engineering

Fetal bone cells for tissue engineering

The effect of an alginate carrier on bone formation in a hydroxyapatite scaffold

MULTIPLE CUTANEOUS METASTASIS FROM CARCINOMA OF THE UTERINE CERVIX Â€“ a CASE REPORT

Contact Info

Product

Resources

About